Jennifer A Soon1, Angelyn Anton1, Javier Torres1, Ruth Lawrence2, Phillip Parente1,3, Joseph McKendrick1,3, Ian D Davis1,3, Carmel Pezaro4,5. 1. Eastern Health Cancer Services, Level 4, 8 Arnold St., Box Hill, VIC, 3128, Australia. 2. Eastern Health Library Services, 5 Arnold St., Box Hill, VIC, 3128, Australia. 3. Monash University Eastern Health Clinical School, 5 Arnold St., Box Hill, VIC, 3128, Australia. 4. Eastern Health Cancer Services, Level 4, 8 Arnold St., Box Hill, VIC, 3128, Australia. carmel.pezaro@monash.edu. 5. Monash University Eastern Health Clinical School, 5 Arnold St., Box Hill, VIC, 3128, Australia. carmel.pezaro@monash.edu.
Abstract
PURPOSE: Testicular seminomas occur in young men and are highly curable. Toxicities following treatment for men with extensive stage II-III seminomas may cause long-term morbidities. However, it is not clear whether the risk of late effects also increases following surgery for testis-confined seminoma. In this systematic review, we examined the available literature regarding the incidence of late effects in our target population of patients with stage I seminoma treated with orchidectomy alone. METHOD: Publications were identified through an electronic literature search using the MEDLINE, EMBASE and PsychInfo databases, identifying cohorts treated for stage I seminoma. Data on late effects were collected and classified as physical or psychological. RESULTS: Six hundred and four articles were screened to identify 100 studies. In the target population, available evidence suggests no increased risk of cardiovascular disease, metabolic syndrome, or renal dysfunction compared to the general population. Sperm counts were initially lower than an age-matched cohort; however, counts normalised when re-assessed 5 years later. Data were not specifically reported for the target population regarding bone health, second malignancy, hypogonadism, fertility and all psychological domains. Heterogeneity of study design and reporting methods contributed to uncertainty regarding the true incidence and clinical significance of late effects. CONCLUSIONS: The curability of stage I seminoma and the wide range of potential late effects of treatment suggest the need for long-term monitoring alongside standard cancer surveillance. Important data are needed on the prevalence of late effects, specifically related to testicular cancer survivors undergoing surveillance following orchidectomy. IMPLICATIONS FOR CANCER SURVIVORS: Awareness and screening for relevant late effects may prevent further morbidity in men treated for stage I seminoma.
PURPOSE:Testicular seminomas occur in young men and are highly curable. Toxicities following treatment for men with extensive stage II-III seminomas may cause long-term morbidities. However, it is not clear whether the risk of late effects also increases following surgery for testis-confined seminoma. In this systematic review, we examined the available literature regarding the incidence of late effects in our target population of patients with stage I seminoma treated with orchidectomy alone. METHOD: Publications were identified through an electronic literature search using the MEDLINE, EMBASE and PsychInfo databases, identifying cohorts treated for stage I seminoma. Data on late effects were collected and classified as physical or psychological. RESULTS: Six hundred and four articles were screened to identify 100 studies. In the target population, available evidence suggests no increased risk of cardiovascular disease, metabolic syndrome, or renal dysfunction compared to the general population. Sperm counts were initially lower than an age-matched cohort; however, counts normalised when re-assessed 5 years later. Data were not specifically reported for the target population regarding bone health, second malignancy, hypogonadism, fertility and all psychological domains. Heterogeneity of study design and reporting methods contributed to uncertainty regarding the true incidence and clinical significance of late effects. CONCLUSIONS: The curability of stage I seminoma and the wide range of potential late effects of treatment suggest the need for long-term monitoring alongside standard cancer surveillance. Important data are needed on the prevalence of late effects, specifically related to testicular cancer survivors undergoing surveillance following orchidectomy. IMPLICATIONS FOR CANCER SURVIVORS: Awareness and screening for relevant late effects may prevent further morbidity in men treated for stage I seminoma.
Entities:
Keywords:
Germ cell tumour; Late effects; Seminoma; Survivorship; Systematic review; Testicular cancer
Authors: Carina Nord; Trine Bjøro; Dag Ellingsen; Arnstein Mykletun; Olav Dahl; Olbjørn Klepp; Roy M Bremnes; Erik Wist; Sophie D Fosså Journal: Eur Urol Date: 2003-09 Impact factor: 20.096
Authors: Marrit A Tuinman; Joke Fleer; Dirk Th Sleijfer; Harald J Hoekstra; Josette E H M Hoekstra-Weebers Journal: Support Care Cancer Date: 2005-01-20 Impact factor: 3.603
Authors: Lene Thorsen; Wenche Nystad; Hein Stigum; Olav Dahl; Olbjørn Klepp; Roy M Bremnes; Erik Wist; Sophie D Fosså Journal: Support Care Cancer Date: 2005-03-09 Impact factor: 3.603
Authors: Marrit A Tuinman; Joke Fleer; Harald J Hoekstra; Dirk Th Sleijfer; Josette E H M Hoekstra-Weebers Journal: Eur J Cancer Date: 2004-07 Impact factor: 9.162
Authors: Eric Huyghe; Tomohiro Matsuda; Myriam Daudin; Christine Chevreau; Jean-Marc Bachaud; Pierre Plante; Louis Bujan; Patrick Thonneau Journal: Cancer Date: 2004-02-15 Impact factor: 6.860
Authors: Sophie D Fosså; Ronald de Wit; J Trevor Roberts; Peter M Wilkinson; Pieter H M de Mulder; Graham M Mead; Pat Cook; Linda de Prijck; Sally Stenning; Neil K Aaronson; Andrew Bottomley; Laurence Collette Journal: J Clin Oncol Date: 2003-03-15 Impact factor: 44.544